Status:
TERMINATED
A Study of PF-04217903 in Patients With Advanced Cancer
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosi...
Detailed Description
The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.
Eligibility Criteria
Inclusion
- Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
- Adequate blood cell counts, normal kidney function, and performance status of 0 or 1
Exclusion
- Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
- Prior stem cell transplant
- Active or unstable cardiac disease or heart attack within 12 months of starting study treatment
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00706355
Start Date
August 1 2008
End Date
June 1 2011
Last Update
June 25 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
2
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
4
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115